Bringing Personalized Medicine to Everyday Practice

Jason Colasanti, BS - Molecular Genetics Scientist Isabel Menendez, DVM, PhD - Precision Medicine and Translational Scientist Nicholas Miles, PharmD - Clinical Pharmacology Fellow, Certified in Pharmacogenomics Yana Vorontsova, PharmD, MBA - Clinical Pharmacology Fellow

Personalized, Effective, Quick, and Safe



Problem

3 of physicians know that genetic testing is clinically important, but...

Only ¹/₃ are confident that their training prepared them to work with genetically high risk patients

Only ¼ believed they could find and use reliable information to educate their patients

Owusu Obeng A, Fei K, Levy KD, et al. Physician-Reported Benefits and Barriers to Clinical Implementation of Genomic Medicine: A Multi-Site IGNITE-Network Survey. J Pers Med. 2018;8(3):24. Published 2018 Jul 24. doi:10.3390/jpm8030024

Solution

- Help providers and patients utilize the benefits of precision medicine through:
 - Direct patient counseling services
 - Easy to use software targeted to both providers and patients

Competition and Substitutions

- Competition exists, though is currently sparse, with no company having a large or considerable share of the market and mostly regional:
 - Ex: Genelex (Invitae), established 1987
 - Estimated annual revenue: \$ 7.1 million
 - Geneticure (focused on blood pressure medications, targets patients)







Market Opportunity

- Global pharmacogenetics [PGx] market was USD 5.66
 billion in 2018 and is expected to reach USD 11.01 billion
 by the year 2026, at a CAGR of 8.7%.
- Market opportunity will continue to grow and expand significantly in the coming years
 - PACR is currently lobbying for reducing barriers and increasing patient access to, and coverage of, PGx testing

Business Model

Value Creation: Our model provides precision medicine to those who need it by working directly with providers and patients to provide education and recommendations

Value Delivery: Our provider aiding software will be available through a subscription based model, including access to on demand counseling and education virtually through the application


Value Extraction: Our model provides profits through direct patient management in collaboration with physicians, while also providing revenue from providers that only wish to use our software to aid their practice

Technology Validation


Personalized medicine: "the right dose of the right drug for the right indication for the right patient at the right time"

More than 70 "personalized" drugs already on the market

Numerous publications in peer reviewed journals




Customer Validation



- Connecting the gap between two existing entities:
 Health care workers/pharmacists and genetic
 - testing labs to provide personalized medicine
- The economic case for a precision medicine can be made by comparing its cost vs health consequences to the current standard of care
 - NIH currently sponsors ongoing research for precision medicine, including pharmacogenetics

Product Development



Secret Sauce and NDA

- **Clinical support** pharmacists specialized in PGx
- User friendly PGx software for providers and patients
- Frictionless results follow the patients between providers, lowering costs of the healthcare system
- Affordable contracting with laboratories to help bring down price for uninsured patients

*Software & Design details available with non-disclosure agreement

Exit Potential

Acquirer	Target	Price
Invitae	Genelex, YouScript	\$20.7 million (2020)
Berkshire Hathaway	Precision Medicine Group	\$275 million (2017)
Blackstone	Precision Medicine Group (from Berkshire Hathaway)	\$2.3 billion (~2021)

Note: Price of acquisitions have been steadily increasing over time

Financials

Financials	Year 1	Year 2	Year 3	Year 4	Year 5
Revenue	\$400,000	\$600,000	\$1,200,000	\$4,900,000	\$21,000,000
Expenses	\$345,000	\$500,000	\$650,000	\$1,100,000	\$2,000,000
Net	\$55,000	\$100,000	\$550,000	\$3,800,000	\$19,000,000

Risk Mitigation & Use of Funds

Risk factor	Risk mitigation strategy
Providers lack of PGx knowledge and wide-spread use	PGx consulting by a collaborative team of genetic pharmacists and medical geneticist
	Educational support through software and CME
Reimbursement	Collaborative Practice Agreement Subscription based model Laboratory contracts
Customer app use	Patients will embrace our friendly, easy, and convenient app with tradicional customer support (i.e. phone call) as the alternative



Leadership Team

Executive Team

Jason Colasanti, BS

Emre Toker, MS

Jamaine Davis, PhD

Scientific Advisory Team

Isabel Menendez, DVM, PhD

Rhonda Soest, RN, MBA

Business Advisory Team

Nicholas Miles, PharmD

Yana Vorontsova, PharmD, MBA